Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Clinical trial NCT05422794 · RECRUITING

Trial details

NCT number: NCT05422794
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Locally Advanced Triple-Negative Breast Carcinoma Metastatic Triple-Negative Breast Carcinoma Unresectable Triple-Negative Breast Carcinoma

Start date: 2023-05-18
Primary completion: 2027-03-31
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.